In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), with a price target of $150. The company’s shares opened today at $156.31.
Rivkind Koffler commented:
“We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.2% and a 46.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.
Currently, the analyst consensus on Jazz Pharmaceuticals is Strong Buy and the average price target is $185.30, representing a 18.5% upside.
In a report released today, H.C. Wainwright also reiterated a Hold rating on the stock with a $160 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $162.59 and a one-year low of $128.58. Currently, Jazz Pharmaceuticals has an average volume of 404.3K.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
